BMS-986263

DRUG4 trials

Sponsors

Bristol-Myers Squibb

Conditions

FibrosisHepatic CirrhosisHepatic ImpairmentLiver FibrosisNonalcoholic Steatohepatitis (NASH)

Phase 1

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

CompletedNCT03142165

Bristol-Myers SquibbFibrosis

Start: 2017-05-11End: 2017-11-29Updated: 2018-01-12

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

CompletedNCT04225936

Bristol-Myers SquibbHepatic Impairment

Start: 2020-01-16End: 2021-06-01Updated: 2021-11-05

Phase 2

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

CompletedNCT03420768

Bristol-Myers SquibbHepatic Cirrhosis, Liver Fibrosis

Start: 2018-02-14End: 2019-05-28Updated: 2022-02-04

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

TerminatedNCT04267393

Bristol-Myers SquibbNonalcoholic Steatohepatitis (NASH)

Start: 2021-03-17End: 2024-02-09Updated: 2024-09-04

Related Papers

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

Hepatology2021-10-0489 citations